Status:
COMPLETED
A Study Of PF-04449913 In Select Hematologic Malignancies
Lead Sponsor:
Pfizer
Conditions:
Hematologic Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies.
Eligibility Criteria
Inclusion
- Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies. They may be newly diagnosed and previously untreated, but not eligible for standard treatment options, or for whom standard therapies are not anticipated to result in a durable response.
- ECOG performance status 0 to 2
- Adequate organ function
Exclusion
- Patients with active CNS disease
- Patient with active malignancy with the exception of basal cell carcinoma, non melanoma skin cancer, carcinoma in situ cervical or skin cancer
- Active GVHD other than Grade 1 skin involvement
- Known malabsorption syndrome
- Patient has an active, life threatening or clinically significant uncontrolled systemic infection
Key Trial Info
Start Date :
March 3 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 27 2013
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00953758
Start Date
March 3 2010
End Date
February 27 2013
Last Update
April 25 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSD Medical Center - La Jolla
La Jolla, California, United States, 92037
2
Moores UCSD Cancer Center
La Jolla, California, United States, 92093
3
UCSD Medical Center - Hillcrest
San Diego, California, United States, 92103
4
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030-4009